Brokerages Set Altimmune, Inc. (NASDAQ:ALT) Price Target at $18.80

Shares of Altimmune, Inc. (NASDAQ:ALT) have earned a consensus recommendation of “Moderate Buy” from the seven brokerages that are currently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $18.80.

A number of analysts have recently issued reports on the company. Piper Sandler reaffirmed an “overweight” rating and set a $25.00 target price on shares of Altimmune in a research report on Friday, June 21st. HC Wainwright restated a “buy” rating and set a $12.00 price objective on shares of Altimmune in a report on Tuesday, May 14th. Guggenheim lowered Altimmune from a “buy” rating to a “neutral” rating in a research report on Monday, April 29th. Evercore ISI raised shares of Altimmune to a “strong-buy” rating in a research report on Friday, August 9th. Finally, JMP Securities dropped their price target on shares of Altimmune from $25.00 to $24.00 and set a “market outperform” rating for the company in a research note on Friday, May 10th.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. North Star Investment Management Corp. bought a new stake in shares of Altimmune in the 1st quarter valued at approximately $31,000. CANADA LIFE ASSURANCE Co acquired a new position in Altimmune in the first quarter worth $44,000. Russell Investments Group Ltd. increased its stake in Altimmune by 1,150.9% during the fourth quarter. Russell Investments Group Ltd. now owns 4,303 shares of the company’s stock valued at $48,000 after purchasing an additional 3,959 shares during the last quarter. TFO Wealth Partners LLC acquired a new stake in shares of Altimmune during the first quarter worth $51,000. Finally, Horizon Wealth Management LLC bought a new position in shares of Altimmune in the 2nd quarter worth about $66,000. Institutional investors own 78.05% of the company’s stock.

Altimmune Stock Up 4.0 %

ALT opened at $6.49 on Friday. The firm’s 50 day moving average is $6.55 and its 200-day moving average is $7.97. Altimmune has a 52-week low of $2.09 and a 52-week high of $14.84. The firm has a market capitalization of $460.15 million, a P/E ratio of -4.08 and a beta of 0.13.

Altimmune (NASDAQ:ALT) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). Altimmune had a negative net margin of 22,645.37% and a negative return on equity of 46.96%. The firm had revenue of $0.01 million for the quarter. During the same period last year, the firm posted ($0.32) earnings per share. Equities analysts expect that Altimmune will post -1.34 earnings per share for the current fiscal year.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.